Compass Pathways Launches TRD Education Campaign at Psych Congress 2026

Key Points

• Compass Pathways will introduce its U.S. healthcare-provider education campaign, Change the Tune in TRD, at Psych Congress 2026 in New Orleans.
• The campaign focuses on the neurobiology of treatment-resistant depression and pathways for managing the condition.
• Compass will present seven posters, including four new health economics and outcomes research presentations and three analyses from its COMP360 psilocybin program.
• Psych Congress 2026 runs from September 14 through September 19.
• COMP360 remains investigational and has not been approved for treatment-resistant depression.

Compass Pathways (Nasdaq: CMPS) will use Psych Congress 2026 to introduce a new educational program for U.S. healthcare providers focused on treatment-resistant depression, or TRD.

The company will also present seven scientific posters, including new research on the real-world burden of treatment-resistant depression and additional analyses from its COMP360 psilocybin clinical development program.

New Campaign Focuses on Treatment-Resistant Depression Education

Compass will debut its Change the Tune in TRD campaign during a three-panel Innovation session on September 15.

The program is designed to help U.S. healthcare providers better understand the neurobiology of treatment-resistant depression and navigate patient-care pathways.

Featured participants include Saundra Jain, a psychotherapist and adjunct clinical affiliate at the University of Texas at Austin School of Nursing; Bryan B. Shapiro, a psychiatrist and assistant clinical professor at UC Irvine Medical Center; and Sandhya Prashad, an interventional psychiatrist and founder of Houston Ketamine Therapeutics and Houston TMS Therapeutics.

Compass will also operate a disease-state booth at Booth #901 and a medical booth at Booth #937 during the conference.

New Research Examines Costs, Care Barriers, and Provider Views

Compass plans to present four new health economics and outcomes research, or HEOR, posters focused on the real-world impact of treatment-resistant depression.

The presentations will address:

• Real-world healthcare costs and resource use across different health states among people with TRD.
• Characteristics of depression episodes used to define real-world health states for major depressive disorder and TRD.
• Behavioral-health provider perspectives on managing people with treatment-resistant depression.
• Clinical practice patterns and barriers to identifying treatment-resistant depression in real-world settings.

The poster presentations are intended to highlight the financial, healthcare-system, and patient-care burdens associated with treatment-resistant depression.

Compass Will Present Additional COMP360 Phase 3 Analyses

The company will also present three encore posters from its COMP360 psilocybin program for treatment-resistant depression.

The presentations will cover patient demographic and clinical characteristics across two pivotal Phase 3 trials, 26-week safety and durability findings from a double-blind, randomized, controlled Phase 3 study, and combined efficacy and safety findings from two Phase 3 trials.

The announcement does not disclose new clinical outcomes from the COMP360 program. The Phase 3 presentations are described as encore analyses, meaning they are repeat presentations of previously presented research.

Treatment-Resistant Depression Remains a Significant Unmet Need

Treatment-resistant depression generally refers to major depressive disorder that has not responded adequately to two or more appropriate courses of approved medication.

Compass estimates that around 4 million people in the U.S. with major depressive disorder live with treatment-resistant depression. The condition can be associated with ongoing symptoms, reduced quality of life, more coexisting health conditions, higher mortality, and greater suicide risk than non-treatment-resistant depression.

Compass’ Psych Congress activities focus on disease education, healthcare-provider engagement, and scientific communication. The event does not represent a regulatory decision, product approval, or commercial launch for COMP360.

COMP360 psilocybin remains an investigational treatment. Its future will depend on clinical findings, regulatory review, safety and efficacy assessments, and the company’s ability to establish an appropriate treatment and care-delivery model if approved